01—Abstract
Summary
Summary of the 10-K filed March 3, 2006. Cited figures are marked; the original filing is the authoritative source.
Biogen Idec's 2005 10-K (filed March 3, 2006) shows a company in transition.
Total 2005 revenues rose 10% to $2.42 billiona from $2.21 billion, driven by AVONEX ($1.54 billion, up 9%) and RITUXAN copromotion and royalty income from Genentech and Roche. Net income improved sharply to $160.7 million ($0.47 diluted EPS) from $25.1 million in 2004, though this was still weighed down by $302 million of intangible amortization, a $118 million facility impairment and loss on the Oceanside NIMO plant sale, $66 million of purchase-accounting inventory costs for AMEVIVE, and $747.7 million of R&D spending. The filing's dominant risk is TYSABRI.
Sales were suspended in February 2005 after progressive multifocal leukoencephalopathy (PML) cases, two of them fatal. An sBLA for MS was under FDA Priority Review with action expected around March 2006, and an advisory committee was scheduled for March 7, 2006. Management states that the outcome could range from permanent withdrawal to restricted-label reintroduction with a black box warning, and that the company could take inventory, intangible, or goodwill write-offs if it cannot return the drug.
Several securities class actions, derivative suits, an SEC investigation, and product liability suits relate to the suspension. To address this, management launched a comprehensive strategic plan in September 2005 that cut about 17%b of the workforce (roughly 650 positions), is divesting AMEVIVE and non-core Oceanside assets, and commits significant capital to external business development.
Liquidity remains solid, with $2.1 billionc in cash and marketable securities and $889.5 million of operating cash flow, though 2005 included $746.4 million to repurchase most of the 2002 senior notes and $322.6 million in buybacks. The RITUXAN rheumatoid arthritis indication was approved in February 2006, and the company's future growth depends heavily on TYSABRI's regulatory path and on AVONEX facing rising MS competition.
02—Key points
Key Highlights
- Revenue grew 10% to $2.42 billion in 2005, with AVONEX product sales of $1.54 billion (up 9%) and RITUXAN U.S. copromotion profit share of $513.8 million (up 12%).
- Net income rose to $160.7 million ($0.47 diluted EPS) from $25.1 million in 2004, though 2005 results absorbed large non-recurring charges including the NIMO sale loss and AMEVIVE inventory write-downs.
- TYSABRI remains suspended after PML cases (two fatal). Its FDA sBLA for MS had a March 2006 action date and a March 7, 2006 advisory committee, and its future commercial availability is uncertain.
- Workforce cut ~17% (~650 positions) under the September 2005 strategic plan, which also divests AMEVIVE and non-core Oceanside real estate and commits significant capital to external R&D and business development.
- Cash, cash equivalents and marketable securities were $2.06 billion at year-end, with $889.5 million of operating cash flow. Cash was used to repurchase $746.4 million of senior notes and $322.6 million of stock.
- Revenue is concentrated: AVONEX and RITUXAN represented about 93% of 2005 revenues, and the RITUXAN-related joint business supplied 29% of total revenue.
- Litigation exposure is significant: securities class actions, derivative suits, an SEC formal investigation, a False Claims Act suit over RITUXAN off-label promotion, and Average Wholesale Price suits. Management has not estimated potential losses for most of these.
03—Questions
Frequently Asked Questions
What is the outlook for TYSABRI, and how much does it matter to the company?
TYSABRI generated only $4.7 million of 2005 sales because of the February 2005 suspension. Its return to market depends on FDA action on the MS sBLA (Priority Review, decision expected around March 2006, advisory committee March 7, 2006) and on EMEA review. The outcome could range from withdrawal to restricted reintroduction with a black box warning. Management has said that failure to return TYSABRI could cause material write-offs and further workforce reductions. The drug is also central to the Hillerod, Denmark manufacturing plans.
Is AVONEX's growth sustainable given rising competition?
AVONEX sales rose to $1.54 billion in 2005 and remain the most prescribed MS therapy worldwide, with more than 130,000 patients. However, management expects increasing competition from REBIF, BETASERON, COPAXONE, and a possible TYSABRI reintroduction. U.S. growth in 2005 came mainly from price increases, with volume declining, so future growth will depend on competitive performance.
How did the strategic plan and restructuring affect results?
The September 2005 plan cut about 650 positions (17% of staff) and recorded $31.4 million of severance and related charges, with $20.0 million in R&D and $11.4 million in SG&A. Facility impairments and the NIMO sale produced a combined $118.1 million charge. The company expects R&D and SG&A to rise in 2006 as it invests in external opportunities and litigation costs grow.
What are the main legal and regulatory risks disclosed?
Key risks include the TYSABRI securities class actions and derivative suits (some dismissed or consolidated), a formal SEC investigation begun in April 2005, a Senate Finance Committee information request, product liability suits tied to TYSABRI PML, a Department of Justice investigation of RITUXAN promotion (via Genentech), and a False Claims Act complaint alleging off-label RITUXAN promotion for RA. Average Wholesale Price suits by multiple states and counties are also pending. Management says it cannot estimate potential losses for most matters.
04—Continue